Exero Medical Appoints Gastrointestinal Surgery Expert Dr. Deborah Nagle to its Scientific Advisory Board
Honored surgeon to offer expertise and guidance to further enhance Exero’s platform for early detection of anastomotic leaks
OR YEHUDA, ISRAEL – February XX, 2021 – Exero Medical, developer of a wireless system for early detection of anastomotic leaks (AL) following gastrointestinal (GI) surgery, today announced the appointment of Dr. Deborah Nagle, Chief of the Colon and Rectal Division of Renaissance School of Medicine at Stony Brook University, to its scientific advisory board.
“We are delighted to welcome Dr. Nagle, whose vast experience both in GI surgery and the development of medical devices will be invaluable in the continued advancement of our AL detection system,” said Erez Shor, CEO of Exero Medical. “With her extensive inter-disciplinary experience, Dr. Nagle brings a unique point of view which combines the insight of a surgeon with the in-depth knowledge of a medical device industry expert, which will ultimately enable safer care of GI surgery patients.”
Dr. Nagle, certified by the American Board of Surgery and the American Board of Colon and Rectal Surgery, was previously the Medical Director for Ethicon where she played a pivotal role in the development of surgical products and innovation strategies in the care of patients with colorectal diseases. She has also been Chief of the Division of Colon and Rectal Surgery at Beth Israel Deaconess Medical Center where she introduced, developed and promoted the use of minimally invasive colorectal surgical techniques. Dr. Nagle was part of the team that developed the technique of single incision laparoscopic surgery and has been recognized in Boston with Best Doctors honors and nationally, receiving America’s Top Doctors for Cancer honors.
“Anastomotic leaks following GI surgery are a major cause for concern to surgeons as this life-threatening complication is quite common. With no effective way to monitor how a wound is healing internally, it is incredibly difficult to identify a complication before it becomes catastrophic,” said Dr. Nagle. “Exero’s system has the ability to provide surgeons with real-time actionable data to achieve optimal care for each patient and I am energized to work with the Exero Medical team to help address this important issue.”
Dr. Nagle is the third GI expert to be appointed to Exero’s Scientific Advisory Board in the past year, joining Professor Nir Wasserberg, Director of the Colorectal Division at Rabin Medical Center and the Chair of the Israeli Colorectal Society and Charles Knowles, Professor of Surgery at Queen Mary University of London and Consultant Colorectal Surgeon at Barts Health NHS Trust.
About Exero Medical
Founded in 2018 by the MEDX Xelerator, an Israeli Innovation Authority incubator, and Clalit HMO, the largest HMO in Israel. Exero Medical’s goal is to save lives through early detection of anastomotic leaks following gastrointestinal (GI) surgeries, addressing a $2 billion market with its sensor technology. The company has created a patent-pending implantable biodegradable wireless sensor designed to continuously monitor the GI tract near the surgical site, alerting physicians to potential anastomotic leakage post-operation and also enabling early patient discharge by identifying proper tissue healing. Exero Medical is backed by seed investment from the MEDX Xelerator, Boston Scientific, MEDX Ventures and Intellectual Ventures.
For more information, visit https://www.exeromedical.com/.
About MEDX Xelerator
MEDX Xelerator is a leading MedTech incubator formed as an initiative of MEDX Ventures Group together with Boston Scientific, Intellectual Ventures’ Invention Science Fund and Sheba Medical Center. Operating under the auspices of the Israel Innovation Authority, MEDX leverages the healthcare expertise and industry experience of its team with the industry leading insights of its partners to nurture its portfolio companies into successful medical ventures for the benefit of patients and health care professionals. MEDX’s current portfolio companies includes: EndoWays, Append Medical, Exero Medical, and PatenSee, Swift Duct and Dimoveo. Exero was formed as part of MEDX Xelerator’s early stage program, “XLab”.
For more information contact info@medxelerator or visit https://www.medxelerator.com/.
Follow MEDX on LinkedIn.
Exero Medical Media Contact: